---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-034824"
form_type: "8-K"
ticker: "OMER"
cik: "0001285819"
company_name: "OMEROS CORP"
filed_at: "2025-11-13T23:59:59+00:00"
generated_at: "2026-05-16T20:09:42.578990+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Omeros Q3 net loss narrows; Novo Nordisk deal for zaltenibart up to $2.1B

## Summary
- Q3 net loss $30.9M ($0.47/sh) vs $32.2M ($0.56/sh) a year ago; adjusted net loss $22.1M ($0.34/sh).
- Entered up to $2.1B asset purchase/license deal with Novo Nordisk for zaltenibart; $240M upfront at Q4 2025 close.
- Cash $36.1M at Sep 30; Q3 cash burn $22M ex-financing; raised $20.3M from Polar and $9M from ATM in Q3.
- PDUFA date for narsoplimab in TA-TMA extended to Dec 26, 2025; commercial launch team ready with brand YARTEMLEA.
- OMIDRIA royalties $9.2M in Q3 on net sales of $30.5M; operating expenses fell to $26.4M from $35.4M.

## SEC filing metadata
- accession: 0001437749-25-034824
- form_type: 8-K
- ticker: OMER
- cik: 0001285819
- company_name: OMEROS CORP
- filed_at: 2025-11-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1285819/000143774925034824/0001437749-25-034824-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1285819/000143774925034824/omer20250825_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-034824
- JSON: https://secwatch.observer/filing/0001437749-25-034824.json
- Plain text: https://secwatch.observer/filing/0001437749-25-034824.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.